Company intelligence / Profile preview
Cancer Research Horizons
- Ownership
- Private
- Development stage
- Other
Overview
Cancer Research Horizons has contributed to the development of at least fourteen marketed oncology drugs and supports a pipeline spanning early discovery through clinical trials. The company leverages its access to the UK's largest network of cancer researchers to translate academic discoveries into commercial therapies and diagnostics. It has formed over seventy-nine start-ups and generated more than £600 million in royalties/IP revenue. Its impact includes enabling over six million courses of treatment worldwide with drugs it helped develop.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculePeptidesDiagnostic (Device/Data platform)Biologic
- Industry
- Biotech
Drug pipeline
16 assets15 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Cancer Research Horizons.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cancer Research Horizons.